Reason for request
Re-assessment of the actual benefit (AB) and the level of improvement in actual benefit (IAB) at the request of the applicant.
Clinical Benefit
| Low |
The actual benefit of MYOZYME remains low in the treatment of late-onset Pompe disease. |
Clinical Added Value
| minor |
The improvement in actual benefit remains minor (level IV) in the treatment of late-onset Pompe disease. |
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
3Hmpj6vB8VH4sFGR
Listen
